Safety and efficacy of orally administered Fx-1006A in patients with familial amyloid polyneuropathy (FAP): A randomized, double-blind, placebo-controlled study.

Trial Profile

Safety and efficacy of orally administered Fx-1006A in patients with familial amyloid polyneuropathy (FAP): A randomized, double-blind, placebo-controlled study.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 08 Aug 2016

At a glance

  • Drugs Tafamidis meglumine (Primary)
  • Indications Amyloid polyneuropathy
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 08 Aug 2016 According to a Pfizer media release, results of pooled post hoc analysis from this and other two trials (Profiles 275556 and 252196) were published online in Amyloid: The Journal of Protein Folding Disorders.
    • 08 Aug 2016 Results of pooled post hoc analysis from this and other two trials (Profiles 275556 and 252196) published in a Pfizer media release.
    • 23 Jun 2015 Post hoc analysis (supporting tafamidis for delaying progression) results presented at the 1st Congress of the European Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top